US Price Erosion Dents Alembic

Site Re-Inspection Springs Fresh Challenge As Company Remains Bullish Overall On US

Challenging phase for Alembic as continued price erosion in the US hurts earnings, while a compliance re-inspection by the FDA at an injectables site results in 10 observations. Investors believe US sales may have bottomed out at current levels but can the Indian firm bounce back quickly?

biz challenge
Tough Q2 For Alembic • Source: Alamy

Price erosion in the US market dented Alembic Pharmaceuticals Limited in the fiscal second quarter, with a compliance “re-verification” visit at an Indian site by the US Food and Drug Administration that did not end up with an all-clear adding to the short-term challenges for the Indian company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business